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Valvular Heart Disease
Diabetes Mellitus Worsens Diastolic Left Ventricular
Dysfunction in Aortic Stenosis Through Altered Myocardial
Structure and Cardiomyocyte Stiffness
Ineˆs Falca˜o-Pires, PhD; Nazha Hamdani, PhD; Attila Borbe´ly, MD, PhD; Cristina Gavina, MD;
Casper G. Schalkwijk, PhD; Jolanda van der Velden, PhD; Loek van Heerebeek, MD;
Ger J.M. Stienen, PhD; Hans W.M. Niessen, MD, PhD;
Adelino F. Leite-Moreira, MD, PhD; Walter J. Paulus, MD, PhD
Background—Aortic stenosis (AS) and diabetes mellitus (DM) are frequent comorbidities in aging populations. In heart
failure, DM worsens diastolic left ventricular (LV) dysfunction, thereby adversely affecting symptoms and prognosis.
Effects of DM on diastolic LV function were therefore assessed in aortic stenosis, and underlying myocardial
mechanisms were identified.
Methods and Results—Patients referred for aortic valve replacement were subdivided into patients with AS and no DM
(AS; n46) and patients with AS and DM (AS-DM; n16). Preoperative Doppler echocardiography and hemodynam-
ics were implemented with perioperative LV biopsies. Histomorphometry and immunohistochemistry quantified
myocardial collagen volume fraction and myocardial advanced glycation end product deposition. Isolated cardiomyo-
cytes were stretched to 2.2-m sarcomere length to measure resting tension (Fpassive). Expression and phosphorylation
of titin isoforms were analyzed with gel electrophoresis with ProQ Diamond and SYPRO Ruby stains. Reduced LV
end-diastolic distensibility in AS-DM was evident from higher LV end-diastolic pressure (211 mm Hg for AS versus
284 mm Hg for AS-DM; P0.04) at comparable LV end-diastolic volume index and attributed to higher myocardial
collagen volume fraction (AS, 12.91.1% versus AS-DM, 18.22.6%; P0.001), more advanced glycation end
product deposition in arterioles, venules, and capillaries (AS, 14.42.1 score per 1 mm2 versus AS-DM, 31.46.1 score
per 1 mm2; P0.03), and higher Fpassive (AS, 3.51.7 kN/m2 versus AS-DM, 5.10.7 kN/m2; P0.04). Significant
hypophosphorylation of the stiff N2B titin isoform in AS-DM explained the higher Fpassive and normalization of Fpassive
after in vitro treatment with protein kinase A.
Conclusions—Worse diastolic LV dysfunction in AS-DM predisposes to heart failure and results from more myocardial
fibrosis, more intramyocardial vascular advanced glycation end product deposition, and higher cardiomyocyte Fpassive,
which was related to hypophosphorylation of the N2B titin isoform. (Circulation. 2011;124:1151-1159.)
Key Words: aortic valve stenosis  myocytes, cardiac  diabetes mellitus  diastole  fibrosis  titin
 myofilamentary proteins
Diabetes mellitus (DM)–induced diastolic left ventricular(LV) dysfunction is increasingly recognized as an impor-
tant determinant of morbidity and mortality in heart failure. In
patients with DM, high diastolic LV stiffness hinders LV
remodeling after myocardial infarction1,2 and raises LV filling
pressures at similar LV filling volumes in both heart failure (HF)
with reduced LV ejection fraction (HFREF) and HF with normal
LV ejection fraction (HFNEF).3 As a consequence, patients with
DM have a higher incidence of HF after myocardial infarc-
tion1,2,4,5 and a poorer prognosis on either HFREF or HFNEF
development.6–8 Mechanisms responsible for raising myocardial
stiffness in DM consist of excessive fibrosis,9 deposition of
advanced glycation end products (AGEs),10 and high cardio-
myocyte stiffness, evident from an elevated in vitro cardiomyo-
cyte resting tension (Fpassive).3 Their relative contributions to
myocardial stiffness differ in HFREF and HFNEF; fibrosis and
AGEs are more important in HFREF and high Fpassive is more
prominent in HFNEF.3 Like macrovascular complications,11,12
DM-related diastolic LV dysfunction failed to improve during
intensified glycemic control,13 and because of this “hyperglyce-
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mic memory,” involvement of epigenetic processes was recently
suspected.14,15
Clinical Perspective on p 1159
In aortic stenosis (AS), studies on interactions with DM
focused mainly on the progression of sclerocalcific aortic
valve disease, which appeared to be accelerated by the
presence of DM.16–20 Recently, experimental studies have
started to address the combined effect of DM and pressure
overload on diastolic LV function. In insulin-resistant mice,
transverse aortic constriction resulted in more diastolic LV
dysfunction and less survival.21 Suprarenal aortic banding
induced similar results in diabetic rats with slowing of LV
relaxation and blunting of the LV lusitropic response to acute
-adrenergic stimulation.22 The clinical relevance of these
experimental findings has so far been confirmed in the
metabolic syndrome but not in DM. When asymptomatic
mild AS was associated with the metabolic syndrome, dia-
stolic LV dysfunction was more pronounced.23 The present
study extends these observations and investigates whether
there is more diastolic LV dysfunction when symptomatic AS
is associated with DM. Furthermore, by using perioperative
LV myocardial biopsies, the present study explores the
myocardial mechanisms responsible for the more severe
diastolic LV dysfunction that occurs when AS and DM are
comorbidities. Here, we compare fibrosis, AGE deposition,
cardiomyocyte Fpassive, titin isoform composition, and titin
isoform phosphorylation in LV myocardium of AS patients in
the presence or absence of DM.
Methods
Patients
The study population consisted of 62 patients with symptomatic AS
referred for surgical valve replacement and operated on between
January 2006 and December 2008. Symptoms were dyspnea (n30),
angina (n15), and syncope (n17). Patients with atrial fibrillation,
significant valvular lesions other than AS, or significant coronary
stenosis (50%) were excluded. In 16 patients, AS was associated
with DM (AS-DM). A patient had DM if he or she used a
glucose-lowering medication and/or insulin or had a fasting plasma
glucose 7.0 mmol/L.24 No patient was using thiazolidinediones.
Perioperative LV myocardial biopsies were procured during aortic
valve replacement. In all patients, LV biopsy material consisted of
endomyocardial tissue resected from the LV outflow tract (Morrow
procedure) because of concomitant LV outflow tract narrowing. In
each patient, biopsy material was split into 5 to 6 samples (5 mg
each); 3 were formalin-fixed and 2 to 3 were snap-frozen in liquid
nitrogen. The formalin-fixed biopsies were used for quantitative
histomorphometry; the snap-frozen biopsies were used for cardio-
myocyte force measurements and myofilamentary proteomics. The
local ethics committee approved the study protocol, and written
informed consent was obtained from all patients.
The control group consisted of 11 patients and was composed of
2 subgroups: 3 patients with normal LV function and major ventric-
ular arrhythmias in whom transvascular LV biopsies were procured
and 8 explanted donor hearts. Histomorphometric and cardiomyo-
cyte functional data observed in the AS and AS-DM patients were
also compared with similar data derived from previously reported
HFREF and HFNEF patients.3 The HFREF patient population (LV
ejection fraction, 292%) consisted of 36 patients hospitalized for
worsening HF and without significant coronary artery disease or
active lymphocytic infiltration in the LV endomyocardial biopsy.
The HFNEF patient population (LV ejection fraction, 602%)
consisted of 28 patients hospitalized for worsening HF, no signifi-
cant coronary artery disease, and no amyloid deposits in the LV
endomyocardial biopsy.
Quantitative Histomorphometry
Light Microscopy
Light microscopic quantification of cardiomyocyte dimensions and
collagen volume fraction (CVF) has previously been described and
validated.25,26 The histomorphometric analysis of the biopsy samples
was performed on Elastica van Gieson–, hematoxylin and eosin–,
and Picrosirius Red–stained 4-m-thick sections of tissue (5
sections of each sample). Images of these sections were acquired
with a projection microscope (50). Subsequent image analysis with
Slidebook 4.0 software (3I, Denver, CO) was performed to deter-
mine cardiomyocyte diameter (MyD; m) and extent of reactive
interstitial fibrosis, which was expressed as CVF (%). Areas of
reparative and perivascular fibrosis were excluded. We determined
MyD perpendicular to the outer contour of the cell membrane at the
nucleus level in 15 representative myocytes of the section in 24 AS
and 9 AS-DM patients. We calculated CVF as the sum of all
connective tissue areas divided by the sum of connective tissue and
muscle areas averaged over 4 to 6 representative fields of the section
in 23 AS and 9 AS-DM patients. In our laboratory, normal values of
MyD and CVF for LV endomyocardial biopsy material are
13.10.3 m and 5.42.2%, respectively.
Immunohistochemistry
Deposition of AGEs was inferred from measurement of the AGE N-
(carboxymethyl)lysine (CML) in 7 AS and 7 AS-DM patients. In
each patient, 4 to 6 representative fields in 5 tissue sections were
analyzed. Development of the anti-CML monoclonal antibody used
and the immunohistochemical staining technique have previously
been described.27,28 An immunohistochemical AGE score per square
millimeter is reported and was derived as follows: Each positively
stained vessel was given an intensity grade (1weak staining,
2moderate staining, 3intense staining), and the sum of all
positively stained vessels multiplied by their intensity grade was
subsequently divided by the slide area to yield an AGE score per
square millimeter.
Force Measurements in Isolated Cardiomyocytes
Force measurements were performed in single, mechanically isolated
cardiomyocytes as described previously.25,26 Biopsy samples (5-mg
wet weight) of 25 AS and 14 AS-DM patients were defrosted in
relaxing solution, mechanically disrupted, and incubated for 5
minutes in relaxing solution supplemented with 0.2% Triton X-100
to remove all membrane structures. Single cardiomyocytes were
subsequently attached with silicone adhesive between a force trans-
ducer and a piezoelectric motor (3.10.3 cardiomyocytes per pa-
tient). Fpassive was measured at sarcomere lengths ranging from 1.6 to
2.2 m. To assess the reversibility of elevated Fpassive, myocytes
were also incubated in relaxing solution supplemented with the
catalytic subunit of protein kinase A (PKA; 100 U/mL; Sigma;
batch-12K7495) and 6 mmol/L dithiothreitol (MP-Biochemicals).
After 40 minutes of incubation with PKA, Fpassive measurements
were repeated. Force values were normalized for myocyte cross-
sectional area. In our laboratory, Fpassive of normal human cardio-
myocytes is 3.50.4 kN/m2.25
Myofilamentary Protein and Titin
Isoform Phosphorylation
Phosphorylation of troponin I, troponin T, myosin light chain-2,
desmin, and myosin binding protein-C was assessed as previously
described29 in 8 AS and 6 AS-DM patients. Myocardial tissue was
washed 3 times in acetone and dissolved in 1D sample buffer
(62.5 mmol/L TRIS [pH 6.8], 15% glycerol, 1% SDS, and 1.5%
hydroxyethyl disulfide) with 100 mmol/L dithiothreitol, heated (5
minutes at 80°C), and centrifuged (20 minutes at 12 000g and 20°C),
and a sample (30 g dry weight in 12 L) was applied on a 4% to
15% gradient gel (Criterion, BioRad). The gel was run at 100 V for
30 minutes followed by 200 V for 50 minutes and was stained for 1
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hour with ProQ Diamond (Molecular Probes, Eugene, OR) according
to the manufacturer’s instructions. Staining was analyzed with a
LAS-3000 system (Fuji Science Imaging Systems) and AIDA Image
analyzer software (Isotopenmeßgera¨te GmbH, Staubenhardt, Ger-
many). Subsequently, the gel was washed and stained overnight with
Sypro Ruby (Molecular Probes) according to the manufacturer’s
instructions and finally analyzed.
For titin isoform phosphorylation, myocardial tissue samples
from 8 AS and 6 AS-DM patients were homogenized in 50 to 100
L Tris-SDS buffer (pH 6.8) containing 8 g/mL leupeptin
(Peptin Institute, Japan). Protein samples (30 g dry weight in
6 L) were applied on the wells, and titin isoforms were separated
on agarose-strengthened 2% SDS–polyacrylamide gels and
stained for 1 hour with ProQ Diamond and Sypro Ruby as
described above.
Data Analysis
Echocardiographic Data
We derived LV end-systolic volume, LV end-diastolic volume, LV
posterior wall thickness, and interventricular septal thickness from
2-dimensional echocardiograms, and we calculated LV mass index
(LVMI) in accordance with the recent recommendations for cardiac
chamber quantification.30 In our laboratory, the normal values for
LVMI and the ratio of LVMI to LV end-diastolic volume index are
923 g/m2 and 1.270.04, respectively.3,26 Peak aortic valve
velocity, mean aortic transvalvular pressure gradient, and aortic
valve area index were derived from Doppler echocardiographic
examination of the aortic valve. Mean aortic transvalvular pressure
gradient was obtained with the modified Bernoulli equation and
aortic valve area index with the standard continuity equation.
Statistics
Values are given as meanSEM. Single comparisons between AS
and AS-DM were assessed by an unpaired Student t test. Signifi-
cance for categorical variables was determined by the Fisher exact
test. Effects of PKA and sarcomere length in AS and AS-DM were
analyzed by 2-factor repeated-measures ANOVA. Bonferroni-
adjusted t tests served as subsequent multicomparison tests. Rela-
tions between 2 continuous variables were assessed with linear
regression analysis. To assess the relation between LVEDP and
CVF, a multiple regression analysis that accounted for both AS
status (AS versus AS-DM) and CVF was used. Statistical analysis
was performed with SPSS (version 9.0).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Left Ventricular Diastolic Dysfunction in Aortic
Stenosis and Aortic Stenosis With
Diabetes Mellitus
The Table compares clinical and hemodynamic characteris-
tics of AS and AS-DM patients. As evident from the aortic
valve area index and mean aortic transvalvular pressure
gradient, the severity of AS was comparable in AS and
AS-DM patients. Concentric LV hypertrophy was present in
both groups as evident from an LVMI that was significantly
larger than normal (P0.001 for both AS and AS-DM) and
from a ratio of LVMI to LV end-diastolic volume index that
also was significantly larger than normal (P0.001 for both
AS and AS-DM). The extent of concentric LV hypertrophy
was comparable in AS and AS-DM. Left ventricular volumes
and LV ejection fraction were also similar in AS and AS-DM,
but end-diastolic LV distensibility was lower in AS-DM as
evident from a higher LVEDP (P0.04) at a comparable LV
end-diastolic volume index (Figure 1).
Myocardial Fibrosis and Advanced Glycation End
Product Deposition
In Picrosirius Red–stained sections, CVF rose from 10.21.2%
in AS (n23) to 19.16.3% in AS-DM (n9; P0.013; Figure
2A). In hematoxylin and eosin–stained sections, CVF rose
similarly from 12.91.1% in AS to 18.22.6% in AS-DM
(P0.001; Figure 2B). When AS and AS-DM data were pooled,
CVF correlated with LVEDP (r0.60, P0.001; Figure 2C). In
addition, CVF correlated with LVEDP (P0.005) in a multiple
regression analysis that included both AS status (AS versus
AS-DM) and CVF. The CVF in AS-DM tended to be lower than
the previously reported CVF in HFREF patients with DM
(HFREF-DM) (22.42.2%; P0.11).3 Deposition of AGEs
Table. Clinical and Hemodynamic Characteristics of Aortic
Stenosis and Aortic Stenosis–Diabetes Mellitus Patients
AS
(n46)
AS-DM
(n16) P
Age, y 64.82.9 66.92.6 0.58
% by Male, n 23/46 6/16 0.56
Body mass index, kg/m2 27.70.7 28.50.9 0.57
Obesity, n 11/46 2/16 0.48
Hypertension, n 23/46 10/16 0.56
History of smoking, n 6/46 1/16 0.67
Medications, n
ACEIs 15/46 8/16 0.24
-blockers 25/46 9/16 0.99
Diuretics 19/46 11/16 0.08
ARBs 1/46 1/16 0.45
Digoxin 1/46 0/16 0.99
Statins 18/46 8/16 0.56
Insulin 0/46 3/16 0.015
Heart rate, bpm 742 744 0.96
LVPSP, mm Hg 2335 2176 0.24
LVEDP, mm Hg 21.41.4 28.23.7 0.040
CI, L  min1 2.310.11 2.080.20 0.39
LVESV, mL 37.63.4 40.17.4 0.74
LVEDV, mL 94.75.2 1099 0.16
LVEDVI, mL/m2 54.82.0 60.33.9 0.14
LVEF, % 64.61.5 62.12.1 0.35
LVPWT, mm 11.10.3 11.00.4 0.29
IVST, mm 13.80.3 13.60.5 0.82
Peak aortic valve velocity, m/s 4.650.17 4.290.21 0.26
Mean aortic transvalvular
pressure gradient, mm Hg
60.12.6 57.61.9 0.56
AVAI, cm2/m2 0.530.04 0.580.04 0.45
LVMI, g/m2 1325 13715 0.66
LVMI/LVEDVI ratio 2.680.20 2.120.23 0.17
AS indicates aortic stenosis; DM, diabetes mellitus; ACEI, angiotensin
converting enzyme inhibitors; ARB, angiotensin II receptor blockers; LVPSP, left
ventricular (LV) peak-systolic pressure; LVEDP, LV end-diastolic pressure; CI,
cardiac index; LVESV, LV end-systolic volume; LVEDV, LV end-diastolic volume;
LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction; LVPWT, LV
posterior wall thickness; IVST, interventricular-septum thickness; AVAI, aortic
valve area index; and LVMI, LV mass index. Values are given as meanSEM
when appropriate.
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was inferred from CML immunostaining and occurred in endo-
thelial and smooth muscle cells of intramyocardial arterioles,
venules, and capillaries (Figure 3A and 3B). Deposition of
AGEs was significantly higher in AS-DM (n7) than in AS
(n7) patients (31.46.1 versus 14.42.1 score per 1 mm2;
P0.03; Figure 3C).
Cardiomyocyte Dimensions and
Cardiomyocyte Fpassive
The MyD rose progressively from 13.10.3 m in control
myocardium to 22.90.3 m in AS and to 26.40.3 m in
AS-DM (P0.01 for trend). The MyD was higher in AS-DM
(n9) than in AS (n24; P0.001; Figure 4A) patients. The
MyD in AS and AS-DM was larger than the MyD previously
reported in HFNEF patients (19.81.7 m; P0.001) and
HFNEF patients with DM (HFNEF-DM; 22.40.9 m;
P0.001), respectively.3 Fpassive of isolated cardiomyocytes
(Figure 4B) was comparable in AS (n25) (3.70.4 kN/m2)
and control (3.51.7 kN/m2) myocardium but higher in AS-DM
(n14; 5.10.7 kN/m2) than in AS (P0.04; Figure 4C) or
control (P0.04). Fpassive in AS and AS-DM was lower than
Fpassive previously reported respectively in HFNEF (5.10.7
kN/m2; P0.001) and in HFNEF-DM (8.50.9 kN/m2;
P0.007).3 The passive length tension of individual car-
diomyocytes was constructed by measuring Fpassive at
various sarcomere lengths ranging from 1.6 to 2.2 m
(Figure 4D). Compared with AS, the passive length-
tension relation of AS-DM was shifted upward over the
entire range of sarcomere lengths.
Titin Isoform Expression and Titin
Isoform Phosphorylation
There was no significant difference in the titin isoform ratio
(N2BA/N2B) among control (0.390.05; n8),29 AS
(0.610.07; n8), and AS-DM (0.500.07; n6). Relative
phosphorylation (P) of N2B and N2BA titin isoforms (Figure
5A) differed, however, as evident from the P-N2BA/P-N2B
ratio, which was significantly higher in AS-DM compared with
control (P0.001; Figure 5B). The higher P-N2BA/P-N2B ratio
resulted from both significant hypophosphorylation of the stiff
N2B isoform (P0.006) and hyperphosphorylation of the com-
pliant N2BA isoform (P0.005). Hypophosphorylation of the
stiff N2B isoform was in agreement with the higher Fpassive in
AS-DM because phosphorylation of titin lowers cardiomyocyte
Fpassive in an isoform-specific way.31 In AS-DM, the P-N2BA/
P-N2B ratio was also correlated with LVEDP (r0.995,
P0.005; Figure 5C). Involvement of a titin phosphorylation
deficit in the high Fpassive of AS-DM cardiomyocytes was
further supported by administration of PKA to the isolated
cardiomyocytes (Figure 4C), which reduced Fpassive to simi-
larly low values in AS (1.90.2 kN/m2) and AS-DM
(1.90.3 kN/m2).
Phosphorylation status of other myocardial proteins was
comparable between AS and AS-DM (troponin I [AS,
0.560.16 versus AS-DM, 0.420.05]; troponin T [AS,
0.380.09 versus AS-DM, 0.340.04]; myosin light chain-2
[AS, 0.160.15 versus AS-DM, 0.140.08]; desmin [AS,
0.100.04 versus AS-DM, 0.200.05]; and myosin binding
protein-C [AS, 0.150.02 versus AS-DM, 0.170.02]).
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Figure 1. Left ventricular (LV) end-diastolic pressure–LV end-di-
astolic volume index (LVEDP-LVEDVI) relation in aortic stenosis
(AS) and AS–diabetes mellitus (AS-DM) patients. The LV end-di-
astolic distensibility is reduced in AS-DM as evident from higher
LVEDP at comparable LVEDVI.
Figure 2. Myocardial fibrosis. A, Repre-
sentative examples of Picrosirius
Red–stained myocardial sections of aor-
tic stenosis (AS) and AS–diabetes melli-
tus (AS-DM) patients showing more
fibrosis in AS-DM patients. B, Collagen
volume fraction (CVF) was higher in
AS-DM than in AS patients. C, When AS
and AS-DM data were pooled, CVF cor-
related with left ventricular end-diastolic
pressure (r0.60, P0.001). ***P0.001.
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Discussion
Aortic Stenosis and Diabetes Mellitus
as Comorbidities
Because of the rising prevalence of sclerocalcific aortic valve
disease and DM type 2 in aging populations, more patients
present with AS and DM as comorbidities. Most clinical
studies investigating the association of AS and DM focused
on the progression of sclerocalcific aortic valve disease to
significant AS and observed faster progression in the pres-
ence of DM.16–20 Despite numerous studies reporting DM to
attenuate eccentric LV remodeling after myocardial infarc-
tion and to raise diastolic LV stiffness in HFREF or HFNEF
in the absence of coronary artery disease,1–3 myocardial
effects of DM in AS have largely been overlooked, apart from
Figure 3. Advanced glycation end prod-
uct (AGE) deposition. A, Intense AGE
deposition in an intramyocardial venule
in aortic stenosis–diabetes mellitus
(AS-DM). B, The AGE deposition in
AS-DM was limited to endothelial and
smooth muscle cells (arrow) in arterioles
and venules and to endothelial cells in
capillaries. C, The AGE deposition score
was larger in AS-DM than AS patients.
*P0.05.
Figure 4. Cardiomyocyte dimension and
Fpassive. A, Cardiomyocyte diameter
(MyD) was higher in aortic stenosis–
diabetes mellitus (AS-DM) than in AS
patients. B, Single cardiomyocyte
mounted between a force transducer
and a piezoelectric motor to measure
Fpassive. C, Fpassive was higher in cardio-
myocytes of AS-DM than AS patients.
Protein kinase A (PKA) decreased
Fpassive in cardiomyocytes of AS and
AS-DM patients. D, Cardiomyocyte pas-
sive length-tension relation was shifted
upward in AS-DM compared with AS
patients. SL indicates sarcomere length.
*P0.05 vs AS; ***P0.001 vs AS;
#P0.05 vs before PKA (PKA).
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1 recent study that reported additive adverse hypertrophic LV
remodeling in AS-DM.32 The present study confirmed in AS
the earlier hemodynamic findings observed in HFREF and
HFNEF, namely a significant rise in LV filling pressures at
comparable LV filling volumes consistent with raised end-
diastolic LV stiffness. Because of comparable aortic valve
area indexes and similar prevalences of arterial hypertension
in the AS and AS-DM groups, the worse diastolic LV
dysfunction in the AS-DM patients cannot be ascribed to
unequal loading of the left ventricle. Similar to earlier
observations in HFREF and HFNEF, the rise in diastolic LV
stiffness occurred in the absence of changes in LV ejection
fraction. This confirms that in AS, diastolic LV dysfunction is
a sensitive marker of DM-induced myocardial dysfunction.
From a clinical management perspective, the DM-induced
compromise of diastolic LV function could predispose pa-
tients with sclerocalcific aortic valve disease to earlier devel-
opment of heart failure symptoms and earlier need of aortic
valve replacement.
Mechanisms of Diastolic Left Ventricular
Dysfunction in Aortic Stenosis With
Diabetes Mellitus
Diastolic LV dysfunction in AS has hitherto been attributed
to interstitial fibrosis resulting from an imbalance between
extracellular matrix production and degradation.33,34 The
present study confirmed these findings in that it observed in
AS a CVF twice as high as in control subjects and in AS-DM
a CVF 3 times as high as in control subjects. Furthermore, for
the pooled AS and AS-DM groups, a significant correlation
was observed between CVF and LVEDP. In contrast to
HFNEF patients,25 Fpassive of isolated cardiomyocytes of AS
patients was comparable to that of control subjects and did
not contribute significantly to diastolic LV dysfunction.
In the present study, the worse diastolic LV dysfunction of
AS-DM patients could have resulted not only from more
fibrosis but also from more AGE deposition and raised
cardiomyocyte Fpassive. With the use of light microscopic
immunohistochemical visualization of CML to measure
AGEs deposition, more CML was detected in the endothelial
and smooth muscle cells of intramyocardial arterioles,
venules, and capillaries of the AS-DM patients. This increase
in AGE deposition could be involved in the worse diastolic
LV dysfunction of the AS-DM patients because vascular
AGE deposition blunts endothelial nitric oxide release, as
evident from improved flow-mediated dilation of the brachial
artery in hypertensives treated with an AGE crosslink
breaker35 and because blunted coronary endothelial nitric
oxide release worsens diastolic LV function.36 When light
microscopic visualization of CML was implemented with
electron microscopy, vascular deposition of CML was re-
cently shown to be accompanied by interstitial accumulation
of CML, which can directly reduce myocardial diastolic
distensibility because of collagen crosslinking.37
The findings of the present study differ from a previous
study in HFREF and HFNEF patients free of coronary artery
disease.3 In the present study, DM worsened diastolic LV
dysfunction in AS through fibrosis, AGE deposition, and
raised cardiomyocyte Fpassive. In HFREF, DM worsened
diastolic LV dysfunction mainly through fibrosis, whereas in
HFNEF, DM worsened diastolic LV dysfunction mainly
through raised cardiomyocyte Fpassive. The extent of the
DM-related increase in Fpassive, however, clearly differed
between AS and HFNEF in that cardiomyocyte Fpassive was
significantly higher in HFNEF-DM than in AS-DM patients.
A similar trend was observed for fibrosis with higher CVF in
HFREF-DM than in AS-DM patients. The unequal extent of
the DM-related myocardial effects in AS, HFREF, and
HFNEF suggests that DM stimulates prevailing myocardial
signal transduction pathways specifically activated by the
underlying clinical condition.38
Cardiomyocyte Hypertrophy and Fpassive
The MyD rose progressively from control to AS and to
AS-DM. The larger MyD in AS-DM than in AS patients
corresponded with a trend for higher LVMI. A larger MyD or
higher LVMI was also observed recently in other situations
combining LV pressure overload with deranged metabolism
such as insulin-resistant mice subjected to transverse aortic
constriction,21 streptozotocin-treated rats subjected to su-
prarenal aortic banding,22 and asymptomatic AS patients
suffering from metabolic syndrome.23
An MyD larger than control was associated with higher
Fpassive in AS-DM patients but not in AS patients, whose
cardiomyocyte Fpassive was similar to values previously re-
ported in control subjects.25 Furthermore, the MyD observed
in AS patients was larger than that previously reported in a
Figure 5. Titin isoform expression and phosphorylation. A, Representative examples of titin isoform phosphorylation in aortic stenosis
(AS) and AS–diabetes mellitus (AS-DM) patients. B, Higher P-N2BA/P-N2B ratio in AS-DM. C, Correlation in AS-DM between P-N2BA/
P-N2B ratio and left ventricular end-diastolic pressure (LVEDP; r0.995, P0.005). *P0.001 vs control.
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group of HFNEF patients suffering from arterial hypertension
and without DM.3 Despite this larger MyD, the cardiomyo-
cytes of the AS patients had lower Fpassive than the cardio-
myocytes of the HFNEF patients. The MyD observed in
AS-DM patients was also larger than the MyD previously
reported in HFNEF-DM patients.3 Again, despite this larger
MyD, the cardiomyocytes of the AS-DM patients had lower
Fpassive than the cardiomyocytes of the HFNEF-DM patients.
From these observations, it becomes apparent that cardio-
myocyte hypertrophy is accompanied by reduced cytoskeletal
distensibility in the setting of DM but not necessarily in the
setting of mechanical overload because AS induces no
change in Fpassive, in contrast to arterial hypertension, which
leads to a large increase in Fpassive. The nature of the
mechanical overload, which is more resistive in AS and more
capacitive in arterial hypertension,39,40 could account for this
divergence because distinct types of loading could trigger
different signal transduction pathways for cardiomyocyte
hypertrophy, some of which are harmless and others are
harmful for cytoskeletal distensibility.
A comparison of Fpassive between AS and HFNEF and
between AS-DM and HFNEF-DM challenges an obligatory
cause-effect relationship between cardiomyocyte hypertrophy
and impaired cardiomyocyte distensibility. Clinical observa-
tions reported a similar dissociation between myocardial
hypertrophy and diastolic LV dysfunction. In the Valsartan in
Diastolic Dysfunction (VALIDD) trial, only 3% of hyperten-
sives had significant LV hypertrophy despite all having
diastolic LV dysfunction, evident from a lower-than-normal
lateral mitral annular age-specific relaxation velocity.41 Basic
studies are also supportive of the idea that impaired cardio-
myocyte distensibility does not result from but actually
causes cardiomyocyte hypertrophy. The giant cytoskeletal
protein titin, which determines cardiomyocyte distensibility,
is indeed increasingly recognized as an important mechano-
sensor interacting at sarcomeric Z-disk, I-band, or M-band
regions with prohypertrophic calcineurin–nuclear factor of
activated T cells, mitogen-activated protein kinases, and
extracellular signal-regulated kinase-2 signaling.42
Cardiomyocyte Fpassive and Titin
Isoform Phosphorylation
Overexpression of the stiff N2B titin isoform, titin hypophos-
phorylation by PKA or protein kinase G, titin hyperphosphor-
ylation by protein kinase C, and loop formation within the
titin molecule caused by oxidative stress–induced disulfide
bonds have all been identified as mechanisms that raise the
intrinsic stiffness of titin and cardiomyocyte Fpassive.42,43
Concerning the effects of titin on cardiomyocyte Fpassive, the
present study observed similar expression of titin isoforms in
control subjects, AS patients, and AS-DM patients; hypo-
phosphorylation of the stiff N2B titin isoform in AS-DM
patients; and raised Fpassive in AS-DM patients that normal-
ized after PKA administration. A recent experimental study
showed insulin to enhance N2B titin isoform expression and
titin phosphorylation in rat embryonic cardiomyocytes but
failed to detect altered passive stiffness in skinned cardiac
fibers of streptozotocin-treated rats.44 These findings are in
agreement with the present study insofar as phosphorylation
of the stiff N2B titin isoform was reduced in AS-DM patients.
This reduction in phosphorylation, however, was accompa-
nied by a significant rise in cardiomyocyte Fpassive, which
correlated with LVEDP and which was corrected by admin-
istration of PKA.
Study Limitations
Because LV tissue was procured perioperatively, its avail-
ability was limited. Hence, all histomorphometry, cardiomyo-
cyte function, and proteomics data could not be acquired in a
single patient, and comparison between AS and AS-DM
patients was therefore frequently limited to subgroups of both
populations. Furthermore, the statistical power of the study
was hampered by the small size of the AS and AS-DM
populations.
Conclusions
The present study observed an additional impairment of LV
end-diastolic distensibility when severe, symptomatic AS was
associated with DM. This additional impairment related to
both structural and functional alterations of LV myocardium
consisting of increased interstitial collagen deposition, aug-
mented intramyocardial vascular AGE accumulation, and
higher Fpassive of cardiomyocytes. Relative hypophosphoryla-
tion of the stiff N2B titin isoform in AS-DM myocardium
accounted for the higher Fpassive of AS-DM cardiomyocytes
because in vitro administration of PKA normalized Fpassive.
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CLINICAL PERSPECTIVE
In aging populations, diabetes mellitus (DM) and aortic stenosis (AS) are becoming frequent comorbidities. Studies looking at
the interaction between DM and AS investigated mainly the progression of sclerocalcific valvular dysfunction. In heart failure
(HF), DM raises diastolic left ventricular (LV) stiffness, which adversely affects morbidity and mortality. The DM-related rise
in diastolic LV stiffness was observed both in HF with reduced ejection fraction and in HF with normal ejection fraction. In HF
with reduced ejection fraction, DM affected myocardial stiffness through excessive fibrosis and arteriolar or capillary deposition
of advanced glycation end products, whereas in HF with normal ejection fraction, DM increased myocardial stiffness through
elevation of cardiomyocyte resting tension (Fpassive). The present clinical study extended these observations on DM-related
worsening of diastolic LV stiffness to symptomatic AS and confirmed a similar increase in diastolic LV stiffness in patients
suffering from both AS and DM. This increase was evident from higher LV end-diastolic pressure at comparable LV
end-diastolic volume index. Furthermore, the increase in diastolic LV stiffness was shown to result from all 3 aforementioned
mechanisms, namely excessive fibrosis, intramyocardial vascular advanced glycation end product deposition, and elevated
cardiomyocyte Fpassive. The latter could be attributed to hypophosphorylation of the stiff isoform of the cytoskeletal protein titin,
which is largely responsible for cardiomyocyte Fpassive. The observed increase in diastolic LV stiffness in patients suffering from
both AS and DM could predispose them to earlier development of heart failure symptoms and an earlier need for aortic valve
replacement.
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